We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





GenScript Demonstrates High-Throughput Measurement of Neutralization Antibody Titers in Serum Samples from SARS-CoV-2 Infected Patients

By LabMedica International staff writers
Posted on 15 Dec 2020
Print article
Image: cPass Surrogate Virus Neutralization Test (Photo courtesy of GenScript USA Inc.)
Image: cPass Surrogate Virus Neutralization Test (Photo courtesy of GenScript USA Inc.)
GenScript USA Inc. (Piscataway, NJ, USA) presented its newly available assay termed cPass Surrogate Virus Neutralization Test (cPassTM sVNT) at the all virtual 2020 AACC Annual Scientific Meeting held on December 13-17.

The assay permits the qualitative and quantitative evaluation of neutralizing antibodies in a simple, cost-effective, and high-throughput test. With the oncoming SARS-CoV-2 vaccination programs soon to be initiated globally, many questions have arisen concerning the efficacy and duration of protection. The focus on a subset of immune response antibodies that block and effectively neutralize the interaction between the virus and host cells has become a key measure of vaccine efficacy. However, their measurement is challenging with the pre-existing live cell neutralization tests that are considered gold standard.

Samples from SARS-CoV-2 recovered individuals exhibited differences up to 400-fold in neutralizing antibody titers demonstrating the practical application of cPass sVNT to assess strength of immune response between both infected and vaccinated individuals; level of protection against re-infection, and duration of protection post-infection/vaccination. cPass sVNT detects circulating neutralizing antibodies against SARS-CoV-2 that block the interaction between the receptor binding domain (RBD) of the viral spike glycoprotein with the ACE2 cell surface receptor. This kit would be instrumental in vaccine and therapeutic development as it is suitable for all antibody isotypes and can be used to determine neutralizing antibodies in animal models without modification. The kit will also help in current COVID-19 investigations of sero-prevalence, assessment of herd immunity, longevity of protective immunity, efficacy of different vaccine candidates as well as tracking infection in animals.

Related Links:
GenScript USA Inc.

Platinum Supplier
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Gold Supplier
Automated Staining Unit
RAL Stainer
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Supplier
Spinal Fluid Cell Count Control
Spinalscopics

Print article

Channels

Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more

Molecular Diagnostics

view channel
Image: The PrismRA blood test helps target best treatments for patients with rheumatoid arthritis (Photo courtesy of Scipher Medicine)

Groundbreaking Rheumatoid Arthritis Blood Test Predicts Treatment Response

Rheumatoid arthritis (RA), an autoimmune disease affecting joints and other systems in the body, impacts millions globally. Typically, the initial biologic treatment involves anti-inflammatory drugs from... Read more

Hematology

view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more

Immunology

view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more

Microbiology

view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more

Pathology

view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more

Industry

view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.